NGNE · Neurogene Inc. · Executive Compensation
$27.58
+0.91 (+3.41%)
At close · Nov 4
Return incl. dividend (before tax)
Market Cap
$533.70M
Shares
20.01M
Volume · Nov 4
208.56K
Avg daily vol (3M)
291.93K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Rachel McMinn | Founder and Chief Executive Officer | $3,209,553 |
| Christine Mikail | President and Chief Financial Officer | $2,754,458 |
| Julie Jordan | Chief Medical Officer | $1,472,307 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Rachel McMinn | Founder and Chief Executive Officer | $3,464,815 |
| Christine Mikail | President and Chief Financial Officer | $3,362,174 |
| Julie Jordan | Chief Medical Officer | $2,460,036 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Donna Cochener | Former Interim Chief Executive Officer and General Counsel | $1,827,432 |
| Sean Smith | Former Interim Chief Financial Officer | $1,809,783 |
| Christine Mikail | President and Chief Financial Officer | $1,132,484 |
| Rachel McMinn | Founder and Chief Executive Officer | $1,080,629 |
| Stuart Cobb | Chief Scientific Officer NEOs Prior to the Merger | $784,324 |
| Jonathan G. Drachman | Former Chief Executive Officer and President | $549,983 |
| Jonathan Drachman | Former Chief Executive Officer and President | $549,983 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Donna Cochener | Former Interim Chief Executive Officer and General Counsel | $993,899 |
| Jonathan G. Drachman | Former Chief Executive Officer and President | $902,179 |
| Jonathan Drachman | Former Chief Executive Officer and President | $902,179 |
| Rachel McMinn | Founder and Chief Executive Officer | $656,545 |
| Christine Mikail | President and Chief Financial Officer | $611,714 |
| Stuart Cobb | Chief Scientific Officer NEOs Prior to the Merger | $458,987 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Jonathan Drachman | Chief Executive Officer | $3,823,038 |
| Jonathan G. Drachman | Chief Executive Officer | $3,823,038 |
| David J. Main | Former Chief Executive Officer and President | $1,963,928 |
| Kamran Alam | Interim Chief Financial Officer and Vice President, Finance | $1,199,997 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| David J. Main | Former Chief Executive Officer and President | $4,226,286 |
| Kamran Alam | Interim Chief Financial Officer and Vice President, Finance | $1,755,527 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| David J. Main | Former Chief Executive Officer and President | $3,040,314 |
| Kamran Alam | Interim Chief Financial Officer and Vice President, Finance | $1,430,509 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Christine Mikail | Class II director | Appointed | 2026-04-20 |
| Robert "Keith" Woods | Class II director | Appointed | 2025-06-12 |
| Sarah B. Noonberg | Class II director | Appointed | 2025-06-12 |
| Donna Cochener | Senior Vice President, General Counsel | Appointed | 2024-02-21 |
| Keith Woods | director | Appointed | 2023-12-19 |
| Cory Freedland | director | Appointed | 2023-12-19 |
| Rachel McMinn | director | Appointed | 2023-12-19 |
| Robert Baffi | director | Appointed | 2023-12-19 |
| Rachel McMinn | Chair of the Board | Appointed | 2023-12-19 |
| Rachel McMinn | Chief Executive Officer | Appointed | 2023-12-19 |
| Christine Mikail | President and Chief Financial Officer | Appointed | 2023-12-19 |
| Todd Simpson | director | Resigned | 2023-12-19 |
| M. Cantey Boyd | director | Resigned | 2023-12-19 |
| Erin Lavelle | director | Resigned | 2023-12-19 |
| Martin Babler | director | Resigned | 2023-12-19 |
| Sean Smith | Interim Chief Financial Officer | Terminated | 2023-12-19 |
| Donna M. Cochener | General Counsel | Terminated | 2023-12-19 |
| Donna M. Cochener | Interim Chief Executive Officer | Terminated | 2023-12-19 |
| Priti Patel | Chief Medical Officer | Resigned | 2023-04-03 |
| Sean Smith | Interim Chief Financial Officer | Appointed | 2023-04-03 |
| Jonathan Drachman | President, Chief Executive Officer, principal executive and financial officer and director | Resigned | 2023-04-03 |
| Donna M. Cochener | Interim Chief Executive Officer | Appointed | 2023-04-03 |
| Jonathan G. Drachman, M.D. | director | Resigned | 2023-03-10 |
| Jonathan G. Drachman, M.D. | President, Chief Executive Officer, principal executive and financial officer | Resigned | 2023-03-10 |
Leadership
- David J. Main CEO
- Donna M. Cochener CEO
- Rachel McMinn CEO, Chairman, Board Member
- Christine Mikail CFO, Board Member
- Christine Mikail Cvijic CFO
- Jonathan Drachman CFO
- Robert Ho CFO
- Sean Smith CFO, Chief Accounting Officer
- Donna Cochener General Counsel
- Cory Freedland Board Member
- Keith Woods Board Member
- Robert "Keith" Woods Board Member
- Robert Baffi Board Member
- Rohan Palekar Board Member
- Sarah B. Noonberg Board Member
Key facts
CIK
1404644
CUSIP
64135M105
13F (30d)
23 filings
23 filers
Visit website
Investor relations